Destina Genomica secured €2.2 million via an EIC funding stream to advance LiverAce Combo, a PCR‑free assay that measures RNA (miR‑122) and protein (CK‑18) biomarkers simultaneously for early detection of drug‑induced liver injury (DILI). The company plans to use funds to transition the test from research use only to a CE‑IVD certified product, addressing an unmet need in both drug development safety and clinical hepatology. The assay’s dual analyte, single‑well format targets adoption on established immunoassay platforms.